NCT01105507View on ClinicalTrials.gov

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 12, 2012

Study Completion Date

May 12, 2012

Conditions
Cryopyrin Associated Periodic Syndrome
Interventions
DRUG

canakinumab (company code: ACZ885D)

Trial Locations (2)

Unknown

Alberta Children's Hospital, Department of Pediatrics, Calgary

Queen Elizabeth II Hospital, Halifax

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY